Archive

« Older Entries

Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update Thursday, December 27th, 2018
Clinical milestones for four lead Biclonics® programs expected in 2019 Cash expected to be sufficient to fund operations into the second quarter of 2021 UTRECHT, The Netherlands, Dec. 27, 2018 (GLOBE NEWSW [...]
Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals Thursday, December 20th, 2018
Merus and Regeneron to cross-license patents relating to certain antibody generation platform technologies   Regeneron to purchase $15 million of Merus common shares  UTRECHT, The Netherlands, Dec. 20, [...]
Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise Monday, December 17th, 2018
Successfully raised CHF 16.1 million from existing and new investors Funding secured for fibrin-PTH Phase II in spinal fusion, a huge commercial opportunity First sales of MagnetOs in US and Europe, co [...]
Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised Thursday, December 13th, 2018
Schlieren (Zurich), Switzerland, December 13, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of offered shares and gross proceeds from the rights offering and share placement, [...]
Kuros announces results of rights offering – capital increase will be implemented Wednesday, December 12th, 2018
Schlieren (Zurich), Switzerland, December 12, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of the rights offering, first announced on November 29, 2018, in which a total of 8,013 [...]
Aelin Therapeutics pursues new cancer drugs Wednesday, December 12th, 2018
The young biotech spin-off gains momentum with a VLAIO grant and an investor award   Leuven, December 12, 2018 - Aelin Therapeutics announced today that it has been awarded close to 1M EUR in non-dilutive fund [...]
Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019 Monday, December 10th, 2018
Copenhagen, December 10, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company expects to announce the results [...]
LSP co-leads $17 Million Series A financing in XyloCor Therapeutics to advance gene therapy in cardiovascular disease Thursday, December 6th, 2018
Novel gene therapy for patients with treatment-resistant angina who have no remaining treatment options is ready to enter clinical development Pharmaceutical industry veteran and former GSK executive Al Gian [...]
LSP leads $28 million financing in Lumeon Tuesday, December 4th, 2018
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Lumeon, a digital health company and leader in the field of [...]
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) Monday, December 3rd, 2018
Regulated information – Inside information   Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up to $1.6 billion potentially Janssen to pay arge [...]

« Older Entries

2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

Archive

« Older Entries

Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update Thursday, December 27th, 2018
Clinical milestones for four lead Biclonics® programs expected in 2019 Cash expected to be sufficient to fund operations into the second quarter of 2021 UTRECHT, The Netherlands, Dec. 27, 2018 (GLOBE NEWSW [...]
Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals Thursday, December 20th, 2018
Merus and Regeneron to cross-license patents relating to certain antibody generation platform technologies   Regeneron to purchase $15 million of Merus common shares  UTRECHT, The Netherlands, Dec. 20, [...]
Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise Monday, December 17th, 2018
Successfully raised CHF 16.1 million from existing and new investors Funding secured for fibrin-PTH Phase II in spinal fusion, a huge commercial opportunity First sales of MagnetOs in US and Europe, co [...]
Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised Thursday, December 13th, 2018
Schlieren (Zurich), Switzerland, December 13, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of offered shares and gross proceeds from the rights offering and share placement, [...]
Kuros announces results of rights offering – capital increase will be implemented Wednesday, December 12th, 2018
Schlieren (Zurich), Switzerland, December 12, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of the rights offering, first announced on November 29, 2018, in which a total of 8,013 [...]
Aelin Therapeutics pursues new cancer drugs Wednesday, December 12th, 2018
The young biotech spin-off gains momentum with a VLAIO grant and an investor award   Leuven, December 12, 2018 - Aelin Therapeutics announced today that it has been awarded close to 1M EUR in non-dilutive fund [...]
Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019 Monday, December 10th, 2018
Copenhagen, December 10, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company expects to announce the results [...]
LSP co-leads $17 Million Series A financing in XyloCor Therapeutics to advance gene therapy in cardiovascular disease Thursday, December 6th, 2018
Novel gene therapy for patients with treatment-resistant angina who have no remaining treatment options is ready to enter clinical development Pharmaceutical industry veteran and former GSK executive Al Gian [...]
LSP leads $28 million financing in Lumeon Tuesday, December 4th, 2018
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Lumeon, a digital health company and leader in the field of [...]
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) Monday, December 3rd, 2018
Regulated information – Inside information   Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up to $1.6 billion potentially Janssen to pay arge [...]

« Older Entries

2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview